Former Searle CEO Richard De Schutter is named DuPont Pharmaceuticals chairman. De Schutter was appointed chief administrative officer of Pharmacia when Monsanto merged with Pharmacia & Upjohn in April, and his retirement from the newly merged company was announced in May. Pharmacia said no plans have been made for a replacement. The position of chairman has been vacant since former DuPont Pharmaceuticals Chairman & CEO Kurt Landgraf left the company in May. Nicholas Teti was named new CEO. Teti and De Schutter report to DuPont Chairman Charles Holiday
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
The removal of CBER Director Prasad comes after a wave of right-wing backlash to his appointment over the past few days that was also critical of his decision to ask Sarepta to suspend all sales of the DMD gene therapy Elevidys. FDA reversed its decision the day before Parsad's departure.